• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 8th June 2010

Biosimilars and Data Exclusivity

Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a poor guide; biosimilars possess critically different characteristics. In the seminar, Prof Grabowski explored these…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Prof Henry Grabowski

Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a poor guide; biosimilars possess critically different characteristics. In the seminar, Prof Grabowski explored these differences and presented his analyses of data exclusivity requirements for biologics/biosimilars.

This is the third in our series of posts based on the OHE seminar and summarises the remarks of Prof Henry Grabowski of Duke University.

Prof Henry Grabowski

Data exclusivity is the period of time after a drug is approved before a biosimilar product can enter the market based on an abbreviated regulatory filing that relies at least in part on the innovator’s safety and efficacy data.  For new chemical entities, data exclusivity is 5 years in the US and 10 years in Europe.  The question is whether biologics should have a longer data exclusivity period because of the narrowness of biologic patents, which are primarily process or formulation patents.  Biosimilars may be different enough to not infringe on the innovator’s patent, yet similar enough to qualify for  an abbreviated regulatory approval process. Data exclusivity, then, provides important  protection and incentives.

In determining the appropriate length of a data exclusivity period for biologics, small molecule drugs are not a good guide.  Biologics are characterised by higher discovery costs, longer development times and higher capital investment in manufacturing plants.  Development times for biologics, moreover, have more than doubled in the past 25 years and development progression is fraught with uncertainty because it often relies on venture capital.

Prof Henry Grabowski’s presentation focused on approaches to analysing a ‘reasonable’ data exclusivity period for biologics  He presented a recent analysis for a portfolio of biologic products, using a series of assumptions about sales, production costs, obsolescence and cost to capital that he considers conservative.  Preliminary results showed that breakeven times range from 12.9 to 16.2 years for biologics, without competition from biosimilars.

In estimating the potential effect of biosimilars on breakeven times and incentives for innovation, Prof Grabowski noted that price competition will be substantially less for biosimilars than for generics because of two factors.  On the supply side, development costs for biosimilars are much higher than for generics; on the demand side, uptake of biosimilars will be affected by payer and provider uncertainty about interchangeability.  Overall, market penetration and price erosion will be slower for biosimilars than for generics.

Prof Grabowski pointed out that several attempts have been made to estimate the extent of the impact of biosimilars in the US market.  This includes his own analyses based on ‘complex small molecules’ that experienced generic competition in the US in the late 1990s to mid 2000s.  These molecules, according to the analysis, lost about 40% of market share over two years, compared with 80% for drugs without complex characteristics.  Based on a simulation exercise that focuses on the cost of capital, contribution margins, biosimilar share and price discounts as well as the data exclusivity period, Prof Grabowski suggested that a data exclusivity period of at least 10 to 14 years is needed to encourage continued innovation in biologics.  (These analyses appear in great detail in the publication.)

Estimated Cumulative Net Present Value with 7 Year Data Exclusivity

Editor’s note: The US Biologics Price Competition and Innovation Act of 2009, enacted since this conference, provides for an abbreviated approval process for biosimilars, a 12-year data exclusivity period and FDA determination of ‘interchangeablility’.

Henry G. Grabowski is Professor Emeritus and Director of the Program in Pharmaceutical Health Economics, Duke University.

Publication now available for download: Mattison, N., Mestre-Ferrandiz, J. and Towse, A.  eds (2010) Biosimilars: How much entry and price competition will result? London: Office of Health Economics.

  • Biosimilars
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
  • News
  • May 2020

Indication-Based Pricing: Are We All Onboard?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!